FUDANZHANGJIANG(688505.SH): Injection of FZ-P001 sodium for visual clinical trials of known or suspected malignant lesions in patients with lung cancer has been accepted.

FUDANZHANGJIANG (688505.SH) announced that the company has recently received the "Acceptance Letter" issued by the National Medical Products Administration for the application of phase II clinical trial of injection FZ-P001 sodium for visualizing malignant lesions in patients with known or suspected lung cancer in surgery. The injection of FZ-P001 sodium is a Class 1 new chemical compound independently developed by the company. It is an innovative photosensitizer, with its active ingredient being a molecule composed of folate receptor-targeted small molecules and chlorin-based photosensitizers, which can target malignant tumor tissues with high expression of folate receptor alpha (FR) and fluoresce in the near-infrared region. The company plans to use this drug to develop intraoperative fluorescence guidance technology, indicating the presence of malignant tumor tissue residue and margin status, aiming to improve the surgical resection outcomes of related solid tumors (such as ovarian cancer, lung cancer, etc.), and provide an innovative solution with molecular targeting specificity and multidimensional biological sensing for precision-guided tumor surgery.